BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Clinical Trials
1.7k
Trial Phases
6 Phases
Drug Approvals
11
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (1336 trials with phase data)• Click on a phase to view related trials
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2025-08-12
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 3040
- Registration Number
- NCT07116967
- Locations
- 🇺🇸
Local Institution - 0088, Birmingham, Alabama, United States
🇺🇸Local Institution - 0107, Phoenix, Arizona, United States
🇺🇸Local Institution - 0322, Scottsdale, Arizona, United States
A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
- Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Interventions
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 150
- Registration Number
- NCT07107373
- Locations
- 🇺🇸
University of California, San Francisco (UCSF), San Francisco, California, United States
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
- Conditions
- Urothelial Cancer
- Interventions
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 470
- Registration Number
- NCT07106762
- Locations
- 🇺🇸
Local Institution - 0167, Gilbert, Arizona, United States
🇺🇸Local Institution - 0162, Fullerton, California, United States
🇺🇸Local Institution - 0163, Sacramento, California, United States
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
- Conditions
- Schizophrenia
- Interventions
- Drug: xanomeline and trospium chloride (XT) therapyDrug: xanomeline and trospium chloride (X/T) therapy
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 300
- Registration Number
- NCT07101094
- Locations
- 🇺🇸
Local Institution - 0003, Evanston, Illinois, United States
🇺🇸Local Institution - 0007, Baltimore, Maryland, United States
🇺🇸Local Institution - 0004, Catonsville, Maryland, United States
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 596
- Registration Number
- NCT07100080
- Locations
- 🇺🇸
Local Institution - 0154, Orange, California, United States
🇺🇸Local Institution - 0139, Edwards, Colorado, United States
🇺🇸Local Institution - 0085, Gainesville, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 298
- Next
News
I-Mab Strengthens Leadership Team with Three New Board Appointments and R&D Committee Formation
I-Mab appointed three seasoned biotech executives to key leadership positions, including Dr. Robert Lenz and Ms. Xin Liu to the Board of Directors and Dr. Ken Takeshita to the Scientific Advisory Board.
Bristol Myers Squibb to Present New Cardiovascular Data at ESC Congress 2025, Including Breakthrough Non-Obstructive HCM Trial Results
Bristol Myers Squibb will present new clinical and real-world data for Camzyos (mavacamten) and Eliquis (apixaban) at the European Society of Cardiology Congress 2025 in Madrid.
Agilent's MMR IHC Panel PharmDx Receives FDA Approval as Companion Diagnostic for Colorectal Cancer Immunotherapy
Agilent Technologies received FDA approval for its MMR IHC Panel pharmDx (Dako Omnis) as a companion diagnostic test to identify mismatch repair deficient colorectal cancer patients eligible for Bristol Myers Squibb's Opdivo immunotherapy treatments.
FDA Grants Breakthrough Therapy Designation to Bristol Myers Squibb and SystImmune's Iza-bren for Advanced EGFR-Mutant Lung Cancer
The FDA has granted breakthrough therapy designation to iza-bren, a first-in-class bispecific antibody-drug conjugate developed by Bristol Myers Squibb and SystImmune for treating advanced EGFR-mutant lung cancer.
Bristol-Myers Squibb, Exelixis, and Novartis Advance Pan-Tumor Rollover Study for Long-Term Nivolumab Safety Assessment
Bristol-Myers Squibb, Exelixis, and Novartis are collaborating on the Pan-Tumor Rollover Study to evaluate the long-term safety of nivolumab monotherapy and its combinations across various tumor types.
Repare Therapeutics Reports 52% Reduction in Q2 Loss Amid Strategic Pivot to Licensing Model
Repare Therapeutics narrowed its Q2 2025 GAAP loss per share to $0.39, significantly beating analyst estimates of -$0.56, primarily driven by a $5.7 million gain from technology platform licensing deals.
X4 Pharmaceuticals Secures $60 Million Financing and Installs New Leadership Team
X4 Pharmaceuticals announced a $60 million private placement financing led by Coastlands Capital, Bain Capital Life Sciences, and New Enterprise Associates to support continued development of mavorixafor.
IO Biotech's Melanoma Vaccine Narrowly Misses Primary Endpoint in Phase 3 Trial Despite Promising Subgroup Results
IO Biotech's cancer vaccine Cylembio combined with Keytruda showed a 23% relative risk reduction in disease progression or death compared to Keytruda alone, but narrowly missed statistical significance with a p-value of 0.056.
GSK's TIM-3 Inhibitor Cobolimab Fails Phase III Trial in Advanced Lung Cancer
GSK's anti-TIM-3 monoclonal antibody cobolimab failed to improve overall survival in the Phase III COSTAR trial for advanced non-small cell lung cancer patients previously treated with immunotherapy.
Bristol Myers Squibb and Bain Capital Launch $300M Immunology Drug Development Venture
Bristol Myers Squibb and Bain Capital have formed an independent company backed by $300 million to develop five experimental immunology drugs licensed from Bristol Myers.